Grants awarded under Bayer Hemophilia Awards Program

Grants have been awarded to a number of doctors and researchers in the field of haemophilia as part of a programme operated by multinational healthcare services provider Bayer.
 
A reception was held this week at the International Society on Thrombosis and Haemostasis 2017 Congress in Berlin and it was revealed that 16 recipients in eight countries will benefit from some $2 million (1.6 million pounds) in free funding under the Bayer Hemophilia Awards Program (BHAP).
 
Four medical professionals from the US are among the beneficiaries and projects include research into anxiety among female haemophilia sufferers and the potential of FVIII splicing-switching molecules for tailored haemophilia treatment.
 
This is the 15th year that the BHAP has operated and it is now the largest programme of its kind to support the haemophilia community. Award recipients are decided by a panel of haemophilia doctors, researchers and caregivers from across the globe.
 
Bayer spokesperson Dr Aleksandra Vlajnic commented: "We're proud to support efforts that drive greater understanding of haemophilia and other bleeding disorders to positively impact patients."  

Some 400,000 people worldwide are estimated to be living with haemophilia, the majority of whom are men.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.